Olopatadine
As of the edition of 20 October 2026, Olopatadine is a small molecule: marketed, first approved in 1996 (US); acts on HRH1; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2021
- Kind
- Small molecule
- Brand name
- Pataday Twice Daily Relief
- First approved
- 18 December 1996 (US)
- Approvals on record
- 13 in 6 regions
- Holder of the most recent approval
- Glenmark Specialty; 7 holders in all
- Registered trials
- 33, 2 stopped early
- Disease areas
- Immune system; Eye; Ear, nose and throat; Lungs and airways; Infections; Injuries
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HRH1 | Histamine H1 receptor | P35367 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 3 | 2 | 0 | 1 |
| Phase 3 | 11 | 11 | 0 | 0 |
| Phase 4 | 17 | 16 | 0 | 1 |
| All trials | 33 |